CytoDyn (CYDY) Given a $2.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $2.00 price objective on CytoDyn (OTCMKTS:CYDY) in a research report released on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research firms also recently issued reports on CYDY. Zacks Investment Research upgraded CytoDyn from a hold rating to a buy rating and set a $0.75 price target on the stock in a research note on Tuesday, September 18th. ValuEngine upgraded CytoDyn from a hold rating to a buy rating in a research note on Thursday, November 1st.

CYDY opened at $0.58 on Tuesday. CytoDyn has a one year low of $0.40 and a one year high of $0.84.

CytoDyn (OTCMKTS:CYDY) last released its quarterly earnings data on Tuesday, October 9th. The biotechnology company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). As a group, equities analysts anticipate that CytoDyn will post -0.21 EPS for the current year.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.

Read More: What is the Book Value of a Share?

Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply